#### Association between kidney measurements and 1

#### cognitive performance in patients with ischemic stroke 2

- 3 Running title: Kidney measures and Cognitive Function
- 4
- 5 Author name: Chunyan Zhang<sup>1</sup>, Guofang Xue<sup>1</sup>, Yanjuan Hou<sup>2</sup>, Pengfei Meng<sup>1</sup>,
- 6 Huizhong Gao<sup>1</sup>, Bo Bai<sup>1</sup>, Dongfang Li<sup>1</sup>
- 7
- 8 <sup>1</sup>Author affiliations: Department of Neurology, Second Hospital, Shanxi Medical
- 9 University, 382 Wuyi Road, Taiyuan, Shanxi, China;
- 10 <sup>2</sup>Author affiliations: Department of Nephrology, Second Hospital, Shanxi Medical
- 11 University, 382 Wuyi Road, Taiyuan, Shanxi, China.
- 12 \*Correspondence: Chunyan Zhang
- 13 Address: Second Hospital, Shanxi Medical University, 382 Wuyi Road, Taiyuan, Shanxi,
- 14 China;
- 15 Email: marzipanzcy@126.com
- 16
- 17
- 18
- 19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 20 Abstract

| 21 | <b>Background</b> Relationships between low estimated glomerular filtration rate (eGFR)            |
|----|--|
| 22 | and albuminuria with poorer cognitive performance in patients with ischemic stroke                 |
| 23 | are less clear. Our aim was to retrospectively ascertain the associations between                  |
| 24 | these renal measures and cognitive performance in patients with ischemic stroke.                   |
| 25 | Methods Retrospective analysis was performed on 608 patients with acute                            |
| 26 | ischemic stroke. Urine albumin-creatinine ratio (UACR) and eGFR were obtained                      |
| 27 | from inpatient medical records. Global cognitive function via mini-mental state exam               |
| 28 | (MMSE) and Montreal Cognitive Assessment (MoCA) was determined one month                           |
| 29 | after hospital discharge. The relationship between renal measures and cognitive                    |
| 30 | performance was assessed using univariate and multiple linear regression analyses.                 |
| 31 | <b>Results</b> Patients had an average age of 66.6±4.1 years, and 48% were females.                |
| 32 | Average eGFR and UACR were 88.4±12.9 ml/min/1.73m <sup>2</sup> and 83.6±314.2 mg/g,                |
| 33 | respectively. The number of patients with an eGFR of $\geq$ 90, 60 to 89, and <60                  |
| 34 | ml/min/1.73 m <sup>2</sup> were (371, 61%), (207, 34%) and (30, 5%) respectively. The              |
| 35 | proportions with a UACR <30 mg/g, 30-300mg/g and >300 mg/g were 56%, 39% and                       |
| 36 | 5%. Multivariate adjusted models showed that eGFR was independently associated                     |
| 37 | with MMSE ( $\beta$ = -0.4; 95% CI= -0.5,-0.4; p <0.001) and MoCA ( $\beta$ = -0.6; 95% CI= -0.7,- |
| 38 | 0.5; p <0.001). However, the correlations between UACR and MMSE and MoCA were                      |

- statistically non-significant.
- Conclusion In patients with ischemic stroke, reduced eGFR but not albuminuria
- was associated with lower cognitive performance. These results show that the eGFR
- decline could be an effective indicator of cognitive impairment after a stroke.
- Therefore, regular monitoring and early detection of mild renal dysfunction in
- patients with acute ischemic stroke might be needed.
- Keywords: cognitive performance, elderly, estimated glomerular filtration rate,
- urine albumin-to-creatinine ratio, ischemic stroke

# 58 Introduction

| 59 | Globally, cognitive impairment is a major health problem during old age. Due to         |
|----|---|
| 60 | better living conditions and healthcare, humans have extended lifespans, and this       |
| 61 | has led to a rapid increase in the prevalence of cognitive dysfunction disorders.(1)    |
| 62 | The identification of modifiable risk factors of cognitive decline or dementia is of    |
| 63 | vital importance in developing preventive strategies.(2) Chronic kidney disease (CKD)   |
| 64 | is a global health burden with a high economic cost to health systems. CKD is defined   |
| 65 | by indicators of renal dysfunction, such as estimated glomerular filtration rate        |
| 66 | (eGFR), and kidney damage, such as urine albumin-creatinine ratio (UACR).(3)            |
| 67 | Numerous cross-sectional or longitudinal studies have been performed to explore         |
| 68 | the relationship between kidney disease and cognitive dysfunction, but the available    |
| 69 | data are conflicting.(4-15)   |
| 70 | A recent study on the Northern Ireland Cohort for the Longitudinal Study of Ageing      |
| 71 | (NICOLA) revealed that decreased eGFR had a significant association with an             |
| 72 | increased risk of cognitive dysfunction in a cohort of older adults.(16) The Maastricht |
| 73 | Study found albuminuria but not eGFR to be independently associated with cognitive      |
| 74 | impairment, specifically within the domain of information processing speed.             |
| 75 | However, both albuminuria and eGFR were more significantly associated with              |
| 76 | cognitive impairment in older individuals.(6) A prospective study in a Chinese          |

| 77 | population aged 80 years and more found early-stage CKD to have a correlation with        |
|----|---|
| 78 | cognitive decline.(17) Palmer et al found that in the African-American population         |
| 79 | with type 2 diabetes (T2D), eGFR and albuminuria were associated with cognitive           |
| 80 | dysfunction, even in mild kidney disease.(18) Cognitive impairment was found to           |
| 81 | occur early in CKD.(19) However, Helmer et al did not find an increased risk of           |
| 82 | cognitive decline or dementia to be associated with low eGFR level. Rather, they          |
| 83 | found that a faster decline in eGFR and proteinuria was associated with incidence of      |
| 84 | cognitive impairment and dementia with a vascular component.(20)                          |
| 85 | The incidence of cognitive impairment after cerebrovascular accidents (CVA) in China      |
| 86 | is as high as 80.9%, including 48.91% for cognitive impairment without dementia and       |
| 87 | 32.05% for cognitive impairment with dementia.(21) Patients with CVA are at a high        |
| 88 | risk of suffering cognitive dysfunction. CVA increased the relative risk of dementia by   |
| 89 | 3.7-fold to 6.6-fold in older adults aged 61–74 years, and advanced the onset of          |
| 90 | dementia by nearly 10 years. (22) However, few studies have examined whether the          |
| 91 | association between low eGFR and albuminuria with poorer cognitive performance            |
| 92 | are limited to individuals with high-risk factors or patients with stroke. A longitudinal |
| 93 | study found that CKD was independently related to incident dementia in patients           |
| 94 | with vascular risk factors and partly support a role for common vascular mechanisms       |
| 95 | as the underlying pathophysiology of AD dementia.(23) Recently, a study in patients       |

- 96 with TIA and stroke found CKD was not independently associated with either pre- or
- 97 post-event dementia, suggesting that renal-specific mechanisms are unlikely to play
- 98 an important role in aetiology.(24)
- 99 This study aimed to investigate whether low eGFR and albuminuria, measured by
- 100 UACR, are independently and/or jointly associated with worse cognitive
- 101 performance in patients with ischemic stroke.

102

## **103** Materials and Methods

#### 104 Data source

105 Using a retrospective design, this study analyzed data from 608 patients aged 60 to

- 106 80 years with acute ischemic stroke within 72 hours of onset between January 2016
- 107 and December 2020 from inpatient medical records and a database of cognitive
- 108 assessment results for outpatient visits one month after hospital discharge. Data was
- 109 collected from September 1, 2019. During or after data collection, investigators had
- 110 access to information that could identify individual patients. All patients were no
- 111 history of a cognitive disorder before stroke and were able to complete the
- assessment, excluding patients who could not cooperate with the examination, such
- as aphasia or consciousness disorder. The study was conducted at the Department of
- 114 Neurology, Second Hospital of Shanxi Medical University, Taiyuan, a tertiary hospital

#### in Shanxi, China. This study was approved by the Ethics Committee of the Second

- 116 Hospital of Shanxi Medical University (NO. 2019YX214). The research was
- 117 completed in accordance with Helsinki Declaration. Due to the retrospective nature
- 118 of the study, informed consent of the patients was not required. The data included
- 119 renal function parameters, such as serum creatinine and UACR, and cognitive
- 120 function test findings, such as mini-mental status examination (MMSE) and Montreal
- 121 Cognitive Assessment (MoCA) scores.

#### 122 Clinical and laboratory data

123 Clinical data extracted from hospital records on admission, included systolic and

124 diastolic blood pressure on admission, self-reported demographic characteristics

125 (age, gender, height, weight, years of education, smoking and alcohol consumption

126 status, and diabetes mellitus and hypertension history), laboratory results (total

127 cholesterol, triglyceride, homocysteine, uric acid, fasting glucose, urea, creatinine,

128 and UACR). Additionally, data on neural function assessment (National Institutes of

- 129 Health Stroke Scale [NIHSS] score) were available. All patients were diagnosed as
- 130 large artery atherosclerosis (LAA), cardioembolism (CE), small artery occlusion (SAO),
- 131 stroke of other determined cause (SOC), and stroke of undetermined cause (SUC)
- 132 according to TOAST classification.(25) Body mass index (BMI) was calculated as
- 133 weight (in kilograms) divided by height (in meters) squared. eGFR was calculated
- 134 using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation,
- 135 which is more accurate than the modification of diet in renal disease (MDRD)

136 equation.(26)

7

#### 137 $eGFR=141 \times min(Scr/k,1)^{\alpha} \times max(Scr/k,1)^{-1.209} \times 0.993^{age} \times 1.018[if female]$

- 138 Where serum creatinine (Scr) is expressed in mg/dL and age in years;  $\kappa$  is 0.7 for
- females and 0.9 for males;  $\alpha$  is -0.329 for females and -0.411 for males; min
- 140 indicates the minimum of Scr/ $\kappa$  or 1, and max indicates the maximum of Scr/ $\kappa$  or 1.

## 141 **Cognitive impairment testing**

- 142 All the cognitive function tests were assessed by two neuropsychological assessors
- 143 trained in consistency using MMSE and MoCA one month after hospital discharge.
- 144 The MMSE and MoCA scores ranged from 0 to 30; higher scores indicated better
- 145 cognitive function. MMSE testing components included 30 point within four
- 146 dimensions: ten points for orientation, six for registration and memory, five for
- 147 attention and calculation, and nine for language and visuospatial abilities. MoCA
- 148 testing domains included visuospatial and executive function (5 points), naming (3
- points), memory (5 points), attention (6 points), language/abstraction (5 points) and
- 150 orientation (6 points).
- 151 Statistical analysis

The study was based on analysis of data obtained from a retrospective design.
Patient characteristics were presented as means ± standard deviations (SD) for
continuous variables, and categorical variables were reported as frequencies and
percentages. Differences between groups for continuous data were tested by one-

| 156 | way analysis of variance (ANOVA). Differences between groups for proportions were                       |
|-----|---|
| 157 | tested with a Chi-square test. Data on UACR were not normally distributed;                              |
| 158 | therefore, they were log-transformed before analysis. Standard definitions were                         |
| 159 | used to categorize eGFR data into three groups, comprising $\geq$ 90 ml/min/1.73 m <sup>2</sup> as      |
| 160 | reference, 60–89 ml/min/1.73 m <sup>2</sup> , and <60 ml/min/1.73 m <sup>2</sup> . Thereafter, eGFR was |
| 161 | analyzed as a continuous variable (per 5 mL/min/1.73 m <sup>2</sup> decreased). UACR values             |
| 162 | were categorized as <30 mg albumin/g creatinine (normal to mildly increased as                          |
| 163 | reference), 30–300 mg/g (moderately increased), and >300 mg/g (severely                                 |
| 164 | increased). Multivariate linear regression was used to assess the association                           |
| 165 | between eGFR or UACR and cognitive performance, with eGFR or UACR as the                                |
| 166 | independent variable and MoCA and MMSE scores as the dependent variables. Two                           |
| 167 | models, Models 1 and 2, were used for the regression analysis. Model 1 was crude,                       |
| 168 | and multivariate-adjusted Model 2 was constructed to adjust for potential                               |
| 169 | confounding variables associated with kidney function and/or cognitive function,                        |
| 170 | including age, gender, BMI, education, diabetes and hypertension history, NIHSS                         |
| 171 | score, stroke subtypes, smoking and alcohol consumption status, serum total                             |
| 172 | cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood                     |
| 173 | pressure (SBP), and either eGFR or UACR. Crude and adjusted ß with 95% CIs are                          |
| 174 | presented. Two-tailed P < 0.05 was considered statistically significant. All analyses                   |

175 were performed using Empower (R)(www.empowerstats.com, X&Y Solutions Inc.,

176 Boston, MA) and R (<u>http://www.R-project.org</u>).

177

## 178 **Results**

#### **Population characteristics**

- 180 Table 1 shows demographic and laboratory data on all 608 patients. Patients had a
- 181 mean age of 66.6 years (SD: 4.1 years) and 48% of patients were females. Average
- 182 eGFR and UACR were  $88.4\pm12.9$  ml/min/1.73 m<sup>2</sup> and  $83.6\pm314.2$  mg/g, respectively.
- 183 Levels of eGFR were >90 ml/min/1.73m<sup>2</sup> (N=371, 61%), 60–89 ml/min/1.73m<sup>2</sup>
- 184 (N=207, 34%), and <60 ml/min/1.73m<sup>2</sup> (N=30, 5%). The number of patients with
- 185 UACR<30 mg/g was 338 (56%). Moderately increased UACR, defined as a UACR 30-
- 186 300mg/g, was present in 240(39%) of patients, and severely increased UACR, defined
- as a UACR >300 mg/g, was present in 30(5%) of patients.
- 188 Patients with lower eGFR categories were more likely to be older and former or
- 189 current alcohol consumers and smokers. In addition, they were more likely to have
- 190 diabetes mellitus, and hypertensive disease, and high systolic blood pressure (SBP)
- 191 and diastolic blood pressure (DBP) on admission. Their homocysteine, blood glucose,
- 192 uric acid, and total cholesterol levels were more likely to be higher, as well as a
- 193 higher BMI. The eGFR levels were lower in patients with albuminuria than in normal

| 194 | patients. As compared | with patients w | ith UACR <30 mg/g, | patients with UACR ≥30 |
|-----|-----------------------|-----------------|--------------------|------------------------|
|-----|-----------------------|-----------------|--------------------|------------------------|

- 195 mg/g were more likely to be living with obesity, diabetes mellitus, and hypertensive
- disease. Additionally, they were more likely to have higher SBP and DBP, blood
- 197 glucose, uric acid, and homocysteine levels. Patients had lower cognitive scores in
- 198 the lower eGFR and higher UACR categories (Table 1).

## 199 Independent and combined associations between eGFR and

#### 200 UACR levels and cognitive performance

- 201 Table 2 contains the results of unadjusted and fully adjusted (age, gender, BMI,
- 202 education, diabetes and hypertension history, NIHSS score, stroke subtypes,
- smoking and alcohol consumption status, serum total cholesterol, triglyceride, uric
- acid, homocysteine, fasting glucose, SBP, and eGFR or UACR) models for continuous
- and categorical relationships between measures of renal disease and cognitive tests.
- 206 The correlation between UACR and MMSE and MoCA scores in crude and
- 207 multivariate adjustment were statistically non-significant. In the crude and adjusted
- 208 analyses, no independent associations were observed between UACR, as a category,
- and cognitive performance. Similarly, no independent associations were observed
- when UACR was analyzed as a continuous variable in Models 1 and 2 (Table 2).
- 211 The association between eGFR and the tests of cognitive performance was evaluated
- 212 with crude and multivariable linear regression analyses. eGFR was analyzed as a

| 213 | categorical ( $\geq$ 90, 60-90, and <60 ml/min/1.73 m <sup>2</sup> ) and a continuous (per 5     |
|-----|--|
| 214 | ml/min/1.73 m <sup>2</sup> decrease) variable. In the multivariable adjustment model, for        |
| 215 | patients with eGFR 60–90 ml/min/1.73 m <sup>2</sup> compared to patients with eGFR $\ge$ 90      |
| 216 | ml/min/1.73 m <sup>2</sup> , an association existed between eGFR and MMSE (ß,-0.7; 95%CI, -      |
| 217 | 1.0 to -0.3) and MoCA (ß,-1.4; 95%Cl, -1.7 to -1.0). The association between eGFR                |
| 218 | <60 ml/min/1.73 m <sup>2</sup> and cognitive performance was stronger. In the multivariable      |
| 219 | adjustment model, MMSE and MoCA were (ß,-4.2; 95%CI -5.0,-3.4) and (ß,-5.2;                      |
| 220 | 95%CI -6.1,-4.4), respectively. When examined as a continuous variable (per 5                    |
| 221 | ml/min/1.73 m <sup>2</sup> decrease) in crude and fully adjusted models, eGFR decrements         |
| 222 | were positively associated with lower MMSE and MoCA scores (p<0.001) (Table 2). In               |
| 223 | all cases, lower levels of eGFR were associated with poorer cognitive performance.               |
| 224 | To assess generalizability, a fully adjusted regression model was created for                    |
| 225 | analyzing the subgroups of sex, stroke subtypes, age, SBP, NIHSS, and blood glucose              |
| 226 | levels. The results were similar in the subgroup analyses. No significant interactions           |
| 227 | were found among any of the stratified variables (male versus female, large artery               |
| 228 | versus small vessel occlusion, age, SBP, NIHSS, and blood glucose dichotomized                   |
| 229 | group: higher versus lower) with eGFR or UACR for cognitive testing. (Tables 3 and 4)            |
| 230 | When combined categories of eGFR (<90 and $\geq$ 90 ml/min/1.73 m <sup>2</sup> ) and albuminuria |
| 231 | (<30 and ≥30mg/g) were analyzed, the MMSE and MoCA scores were the least in                      |

12

| 232 | those patients with UACR ≥30 mg/g and eGFR <9 | 0 ml/min/1.73 m <sup>2</sup> , compared to |
|-----|---|--|
|     |   |  |

- those without albuminuria and eGFR level of  $\geq$ 90 ml/min/1.73 m<sup>2</sup> in the crude and
- fully adjusted model (Table 5).
- 235

## 236 **Discussion**

- 237 This study found that in old adults with ischemic stroke in China, reduced eGFR, but
- 238 not albuminuria measured by UACR, has an independent association with poorer
- 239 cognitive performance. This study supports findings from prior studies reporting a
- 240 link between kidney function and cognitive impairment.

#### 241 eGFR and cognitive performance

Our results showed that, in the absence or presence of albuminuria, an eGFR <90 ml/min/1.73 m<sup>2</sup> had an association with worse cognitive performance. However, the presence of albuminuria amplified the relationship. These findings corroborate the

- 245 findings of prior studies on the association between renal measures and poorer
- 246 cognitive performance. According to previous reports, this association exists during
- the early stages of renal dysfunction.(17, 18) The association between renal function
- and cognitive performance has been paid much attention in recent decades. Wang
- et al found that both CKD and eGFR were associated with cognitive dysfunction
- among older patients with hypertension in China.(27) A prospective study

| 251 | demonstrated that kidney dysfunction is associated with a cognitive decline in a       |
|-----|--|
| 252 | community-based population, and this association is independent of                     |
| 253 | albuminuria.(28) Another longitudinal study suggested that a low eGFR was              |
| 254 | associated with increased risk of dementia. In addition, a faster decrease in eGFR     |
| 255 | and proteinuria was associated with incidence of cognitive impairment and              |
| 256 | dementia; this association may be mediated by vascular mechanisms.(20)                 |
| 257 | Additionally, a large population study found that each 10 ml/min/1.73 $m^2$ decrease   |
| 258 | in eGFR<60 ml/min/1.73 m <sup>2</sup> was independently associated with an increased   |
| 259 | prevalence of cognitive impairment.(29) The OSACA2 study found that CKD was            |
| 260 | independently related to incident dementia in patients with vascular risk factors.(23) |
| 261 | However, one cochort study from the Oxford Vascular Study (OXVASC) did not find        |
| 262 | CKD was associated with either pre- or postevent dementia in patients with TIA and     |
| 263 | stroke.(24) The inconsistent results may be attributable to different study            |
| 264 | populations and severity of lesion. OXVASC has focused on the relationship between     |
| 265 | CKD and dementia in the patients with TIA and stroke. Participants in SPRINT were in   |
| 266 | older community-dwelling adults with cardiovascular disease. OSACA2 was in high-       |
| 267 | risk patients for the primary and secondary prevention of cardiovascular disease.      |
| 268 | Another potential reason is different methods of assessment. Many previous studies     |
| 269 | have used different assessment tools to evaluate cognitive function.                   |

| 270 | Although the precise pathophysiologic mechanisms that underlie the association         |
|-----|--|
| 271 | between low eGFR and poorer cognitive performance are not known and need               |
| 272 | further studies for clarity, several factors may help explain the association between  |
| 273 | low eGFR and cognitive dysfunction. Patients with renal dysfunction have a higher      |
| 274 | prevalence of cerebrovascular disease (CVD) than the general population. Renal         |
| 275 | dysfunction may contribute to vascular cognitive impairment through traditional        |
| 276 | CVD risk factors, including hypertension, diabetes mellitus, dyslipidemia, smoking,    |
| 277 | and other non-traditional vascular risk factors comprising hyperhomocysteinemia,       |
| 278 | hyperuricemia, anemia, inflammation, and oxidative stress. Moreover, CKD               |
| 279 | characterized by the accumulation of uremic toxins, excessive RAS activation, renal    |
| 280 | anemia, and renal osteopathy, caused by renal dysfunction are possible mechanisms      |
| 281 | of renal disease involvement in the progression of dementia.(30, 31) Conceptually,     |
| 282 | low eGFR may lead to the accumulation of neurotoxins or may represent a                |
| 283 | prolonged exposure to CVD or its risk factors.(6) Vascular dementia is often linked to |
| 284 | hypertension, which is a common finding in CKD. Hypertension has often been            |
| 285 | associated with small lacunar infarcts and leukoaraiosis, cerebral autoregulation      |
| 286 | dysfunction, and chronic hypoperfusion. Although cerebral blood flow may be            |
| 287 | adequate in CKD, the blood-brain barrier or the glymphatic system might be             |
| 288 | dysfunctional. In this study, more than 50% of the patients had hypertension. Uremic   |

15

| 289 | toxins in circulation, | which enter th | e central nervous s | ystem (CNS | ) as a result of |
|-----|------------------------|----------------|---------------------|------------|------------------|
|-----|------------------------|----------------|---------------------|------------|------------------|

- 290 blood-brain barrier damage during kidney dysfunction, might impair CNS structure
- and function.(32)

## 292 Albuminuria and cognitive performance

- 293 According to recent systematic review and meta-analysis studies, albuminuria has a
- significant association with cognitive impairment and dementia. (4, 33, 34) To the
- 295 best of our knowledge, albuminuria is a significant risk factor for the development of
- 296 dementia in community-based Japanese older adults. Moreover, low eGFR and
- albuminuria are mutually associated with a greater risk of vascular dementia.(35) A
- 298 prospective cohort study demonstrated that persistent or progressive albuminuria is
- associated with cognitive decline in adults with diabetes and normal eGFR.(36) Wei
- 300 et al found that urine albumin is significantly associated with cognitive dysfunction,
- and can be potentially used as an early marker for CKD.(37)
- 302 The mechanism underlying the association between albuminuria and poorer
- 303 cognition is not completely understood and is likely multifactorial. Both cerebral and
- 304 renal circulations have high flow and low impedance. The association between
- 305 albuminuria and cognitive impairment probably reflects common microvascular
- 306 pathogenesis in the kidneys and brain. Several reasons may explain the
- 307 inconsistencies between our findings and those of previous reports. First, the

| 308 | conflicting results may be attributable to use of different study populations in        |
|-----|---|
| 309 | studying the severity of albuminuria. Patients with cognitive dysfunction may reflect   |
| 310 | in another chronic microvascular disease. This may explain why dementia and poorer      |
| 311 | cognitive performance are more common in individuals with diabetes who have a           |
| 312 | high prevalence of albuminuria. (36, 38) However, since fewer patients with diabetes    |
| 313 | participated in this study (8%), these findings should be interpreted with caution.     |
| 314 | The study might be underpowered to detect the association between UACR and              |
| 315 | poorer cognitive performance. Second, this study only measured UACR at a single         |
| 316 | time point. UACR is affected by exercise and the time of day the sample is taken, (39)  |
| 317 | which is why repeated measurements would be preferred. The true association             |
| 318 | between albuminuria and cognitive performance is likely to be diluted. An               |
| 319 | alternative explanation for the disparate results of the association between low        |
| 320 | eGFR and albuminuria and poorer cognitive performance could be that albuminuria         |
| 321 | is a marker for a different condition other than kidney disease.(40)                    |
| 322 | This study had several strengths. First, the primary independent and dependent          |
| 323 | variables were quantified using clinically relevant measures (eGFR and UACR for two     |
| 324 | independent markers of renal function and damage and MoCA and MMSE for                  |
| 325 | cognitive performance), thus providing clinical relevance to the analyses. In addition, |
| 326 | the use of both eGFR and UACR as correlators enabled us to test their independent       |

| 327 | and joint effects on cognitive performance. Second, the study controlled for several              |
|-----|---|
| 328 | potential confounders, including demographic and clinical parameters, while                       |
| 329 | assessing the association.  |
| 330 | Several limitations were noted. First, our study population contained a small number              |
| 331 | of partients with CKD (eGFR <60 ml/min/1.73 m <sup>2</sup> ), which limited our ability to detect |
| 332 | a relationship between eGFR <60 ml/min/1.73 m <sup>2</sup> and cognitive performance.             |
| 333 | Second, these parameters were based on a one-time evaluation and do not provide                   |
| 334 | information on the duration or severity of risk factors over time. Third, we did not              |
| 335 | analyze impairment in specific cognitive domains; instead, overall cognitive scores               |
| 336 | were used in the analysis. Finally, the cognitive assessment was performed one                    |
| 337 | month after hospital discharge, and the incidence of post-stroke cognitive                        |
| 338 | impairment is highest three months after stroke.(41) Further long-term follow-up is               |
| 339 | still needed.   |
| 340 | Our findings support the hypothesis that renal dysfunction and albuminuria may                    |
| 341 | operate through different pathophysiologic mechanisms. They further suggest that                  |
| 342 | the pathways mediating the association between low eGFR and albuminuria and                       |
| 343 | poorer cognitive performance may be partially distinct. The findings have clinical                |
| 344 | implications. Our results suggest that the measurement of eGFR is a good biomarker                |
| 345 | for cognitive impairment in patients with acute ischemic stroke. Low eGFR may                     |

- 346 reflect a partially distinct pathophysiologic process of cognitive dysfunction.
- 347 Targeting the pathogenesis of low eGFR or treating modifiable risk factors may have
- 348 clinical implications in preventing cognitive impairment or delaying disease
- 349 progression. Further studies are needed to confirm whether the setting of kidney
- 350 dysfunction is a possible new determinant for cognitive impairment in patients with
- 351 stroke.
- 352

## 353 Conclusion

- 354 Our findings suggest that in patients with ischemic stroke, reduced eGFR but not
- albuminuria was associated with cognitive impairment, measured by MMSE or MoCA.
- 356 The eGFR decline could be an effective indicator of cognitive impairment after a
- 357 stroke. These results suggest that the early stages of renal dysfunction could be an
- 358 effective target to prevent cognitive impairment in patients with stroke. It
- 359 emphasizes the need and possibility for early detection and early cognitive
- 360 impairment prevention after stroke.
- 361

## 362 Acknowledgments

- 363 None.
- 364

perpetuity. It is made available under a CC-BY 4.0 International license .

## 365 **References**

Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global
 prevalence of dementia: a systematic review and metaanalysis. Alzheimer's &
 dementia : the journal of the Alzheimer's Association. 2013 Jan;9(1):63-75.e2.
 PubMed PMID: 23305823. Epub 2013/01/12. eng.

Plassman BL, Williams JW, Jr., Burke JR, Holsinger T, Benjamin S. Systematic
 review: factors associated with risk for and possible prevention of cognitive decline in
 later life. Annals of internal medicine. 2010 Aug 3;153(3):182-93. PubMed PMID:
 20547887. Epub 2010/06/16. eng.

Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al.
 Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta Analysis. PloS one. 2016;11(7):e0158765. PubMed PMID: 27383068. Pubmed Central
 PMCID: Pmc4934905. Epub 2016/07/08. eng.

Deckers K, Camerino I, van Boxtel MP, Verhey FR, Irving K, Brayne C, et al.
 Dementia risk in renal dysfunction: A systematic review and meta-analysis of
 prospective studies. Neurology. 2017 Jan 10;88(2):198-208. PubMed PMID:
 27974647. Pubmed Central PMCID: Pmc5224710. Epub 2016/12/16. eng.

Weiner DE, Gaussoin SA, Nord J, Auchus AP, Chelune GJ, Chonchol M, et al.
Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood
Pressure Intervention Trial (SPRINT). American journal of kidney diseases : the
official journal of the National Kidney Foundation. 2017 Sep;70(3):357-67. PubMed
PMID: 28606731. Pubmed Central PMCID: Pmc5572661. Epub 2017/06/14. eng.

Martens RJ, Kooman JP, Stehouwer CD, Dagnelie PC, van der Kallen CJ,
Koster A, et al. Estimated GFR, Albuminuria, and Cognitive Performance:
The Maastricht Study. American journal of kidney diseases : the official journal of the
National Kidney Foundation. 2017 Feb;69(2):179-91. PubMed PMID: 27291486. Epub
2016/06/14. eng.

392 7. Ekblad LL, Toppala S, Johansson JK, Koskinen S, Sundvall J, Rinne JO, et al.
393 Albuminuria and Microalbuminuria as Predictors of Cognitive Performance
394 in a General Population: An 11-Year Follow-Up Study. Journal of Alzheimer's disease :
395 JAD. 2018;62(2):635-48. PubMed PMID: 29480195. Epub 2018/02/27. eng.

8. Kong JY, Kim JS, Kang MH, Hwang HS, Won CW, Jeong KH. Renal
dysfunction is associated with decline of cognitive function in community-dwelling
older adults: Korean frailty and aging cohort study. 2020 Nov 10;20(1):462. PubMed
PMID: 33172388.

400 9. Etgen T, Chonchol M, Förstl H, Sander D. Chronic kidney disease and
401 cognitive impairment: a systematic review and meta-analysis. American journal of
402 nephrology. 2012;35(5):474-82. PubMed PMID: 22555151. Epub 2012/05/05. eng.

Kurella Tamura M, Yaffe K, Hsu CY, Yang J, Sozio S, Fischer M, et al.
Cognitive Impairment and Progression of CKD. American journal of kidney diseases :
the official journal of the National Kidney Foundation. 2016 Jul;68(1):77-83. PubMed
PMID: 26972681. Pubmed Central PMCID: Pmc4921255. Epub 2016/03/15. eng.

407 11. Joosten H, Izaks GJ, Slaets JP, de Jong PE, Visser ST, Bilo HJ, et al.
408 Association of cognitive function with albuminuria and eGFR in the general
409 population. Clinical journal of the American Society of Nephrology : CJASN. 2011
410 Jun;6(6):1400-9. PubMed PMID: 21566108. Pubmed Central PMCID: Pmc3109938.
411 Epub 2011/05/14. eng.

Barzilay JI, Younes N, Pop-Busui R, Florez H, Seaquist E, Falck-Ytter C, et al.
The cross-sectional association of renal dysfunction with tests of cognition in middleaged adults with early type 2 diabetes: The GRADE Study. Journal of diabetes and its

perpetuity. It is made available under a CC-BY 4.0 International license .

415 complications. 2021 Mar;35(3):107805. PubMed PMID: 33288412. Pubmed Central 416 PMCID: Pmc7870547. Epub 2020/12/09. eng. 417 13. Feng L, Yap KB, Yeoh LY, Ng TP. Kidney function and cognitive and functional 418 decline in elderly adults: findings from the Singapore longitudinal aging study. 419 Journal of the American Geriatrics Society. 2012 Jul;60(7):1208-14. PubMed PMID: 420 22702744. Epub 2012/06/19. eng. 421 Kono S, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, et al. 14. 422 Impact of cystatin C and microalbuminuria on cognitive impairment in the population 423 of community-dwelling Japanese. Atherosclerosis. 2017 Oct;265:71-7. PubMed PMID: 424 28865325. Epub 2017/09/03. eng. 425 Lee S, Shimada H, Park H, Makizako H, Lee S, Doi T, et al. The association 15. 426 between kidney function and cognitive decline in community-dwelling, elderly 427 Japanese people. Journal of the American Medical Directors Association. 2015 428 Apr;16(4):349.e1-5. PubMed PMID: 25669668. Epub 2015/02/12. eng. 429 16. Paterson EN, Maxwell AP, Kee F, Cruise S, Young IS, McGuinness B, et al. 430 Association of renal impairment with cognitive dysfunction in the Northern Ireland 431 Cohort for the Longitudinal Study of Ageing (NICOLA). 2021 Jul 23;36(8):1492-9. 432 PubMed PMID: 34038557. 433 Bai K, Pan Y, Lu F, Zhao Y, Wang J, Zhang L. Kidney function and cognitive 17. 434 decline in an oldest-old Chinese population. Clinical interventions in aging. 435 2017;12:1049-54. PubMed PMID: 28740370. Pubmed Central PMCID: Pmc5505158. 436 Epub 2017/07/26. eng. 437 18. Palmer ND, Sink KM, Smith SC, Xu J, Bowden DW, Hugenschmidt CE, et al. 438 Kidney disease and cognitive function: African American-diabetes heart study MIND. 439 American journal of nephrology. 2014;40(3):200-7. PubMed PMID: 25323981. 440 Pubmed Central PMCID: Pmc4216628. Epub 2014/10/18. eng. 441 Berger I, Wu S, Masson P, Kelly PJ, Duthie FA, Whiteley W, et al. Cognition in 19. 442 chronic kidney disease: a systematic review and meta-analysis. BMC medicine. 2016 443 Dec 14;14(1):206. PubMed PMID: 27964726. Pubmed Central PMCID: Pmc5155375. 444 Epub 2016/12/15. eng. 445 Helmer C, Stengel B, Metzger M, Froissart M, Massy ZA, Tzourio C, et al. 20. 446 Chronic kidney disease, cognitive decline, and incident dementia: the 3C Study. 447 Neurology. 2011 Dec 6;77(23):2043-51. PubMed PMID: 22116945. Epub 2011/11/26. 448 eng. 449 21. Qu Y, Zhuo L, Li N, Hu Y, Chen W, Zhou Y, et al. Prevalence of post-stroke 450 cognitive impairment in china: a community-based, cross-sectional study. PloS one. 451 2015;10(4):e0122864. PubMed PMID: 25874998. Pubmed Central PMCID: 452 Pmc4395303. Epub 2015/04/16. eng. 453 22. De Ronchi D, Palmer K, Pioggiosi P, Atti AR, Berardi D, Ferrari B, et al. The 454 combined effect of age, education, and stroke on dementia and cognitive impairment 455 no dementia in the elderly. Dementia and geriatric cognitive disorders. 456 2007;24(4):266-73. PubMed PMID: 17700023. Epub 2007/08/19. eng. 457 23. Miwa K, Tanaka M, Okazaki S, Furukado S, Yagita Y, Sakaguchi M, et al. 458 Chronic kidney disease is associated with dementia independent of cerebral small-459 vessel disease. Neurology. 2014 Mar 25;82(12):1051-7. PubMed PMID: 24553427. 460 Epub 2014/02/21. eng. 461 24. Kelly DM, Pendlebury ST. Associations of Chronic Kidney Disease With 462 Dementia Before and After TIA and Stroke: Population-Based Cohort Study. 2022 463 Feb 15;98(7):e711-e20. PubMed PMID: 34996878. 464 Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. 25. 465 Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter

medRxiv preprint doi: https://doi.org/10.1101/2023.09.24.23296045; this version posted September 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

466 clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993 467 Jan;24(1):35-41. PubMed PMID: 7678184. Epub 1993/01/01. eng. 468 26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et 469 al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 470 5;150(9):604-12. PubMed PMID: 19414839. Pubmed Central PMCID: Pmc2763564. 471 Epub 2009/05/06. eng. 472 Wang H, Liu T, Cai YY, Jiang H, Liu HX, Lin C. Kidney Function and Cognitive 27. 473 Impairment in People Aged 80 Years and Over with Untreated Hypertension: A 474 Cross-Sectional Survey. Kidney & blood pressure research. 2016;41(1):70-7. PubMed 475 PMID: 26872346. Epub 2016/02/13. eng. 476 Wang F, Zhang L, Liu L, Wang H. Level of kidney function correlates with 28. 477 cognitive decline. American journal of nephrology. 2010;32(2):117-21. PubMed PMID: 478 20714128. Epub 2010/08/18. eng. 479 29. Kurella Tamura M, Wadley V, Yaffe K, McClure LA, Howard G, Go R, et al. 480 Kidney function and cognitive impairment in US adults: the Reasons for Geographic 481 and Racial Differences in Stroke (REGARDS) Study. American journal of kidney 482 diseases : the official journal of the National Kidney Foundation, 2008 483 Aug; 52(2): 227-34. PubMed PMID: 18585836. Pubmed Central PMCID: Pmc2593146. 484 Epub 2008/07/01. eng. 485 Kurella Tamura M, Xie D, Yaffe K, Cohen DL, Teal V, Kasner SE, et al. 30. 486 Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic 487 Renal Insufficiency Cohort (CRIC) study. Clinical journal of the American Society of 488 Nephrology : CJASN. 2011 Feb;6(2):248-56. PubMed PMID: 20930087. Pubmed 489 Central PMCID: Pmc3052213. Epub 2010/10/12. eng. 490 Zhang J, Tang L, Hu J, Wang Y, Xu Y. Uric acid is associated with cognitive 31. 491 impairment in the elderly patients receiving maintenance hemodialysis-A two-center 492 study. 2020 Mar;10(3):e01542. PubMed PMID: 31985179. Viggiano D, Wagner CA, Martino G. Mechanisms of cognitive dysfunction in 493 32. 494 CKD. 2020 Aug;16(8):452-69. PubMed PMID: 32235904. 495 33. Georgakis MK, Dimitriou NG, Karalexi MA, Mihas C, Nasothimiou EG, 496 Tousoulis D, et al. Albuminuria in Association with Cognitive Function and Dementia: 497 A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society. 498 2017 Jun;65(6):1190-8. PubMed PMID: 28152169. Epub 2017/02/06. eng. 499 34. Li H, Zhao S, Wang R, Gao B. The association between cognitive impairment/dementia and albuminuria: a systematic review and meta-analysis. 500 501 Clinical and experimental nephrology. 2021 Aug 28. PubMed PMID: 34468878. Epub 502 2021/09/02. eng. 503 Takae K, Hata J, Ohara T, Yoshida D, Shibata M, Mukai N, et al. Albuminuria 35. 504 Increases the Risks for Both Alzheimer Disease and Vascular Dementia in 505 Community-Dwelling Japanese Elderly: The Hisayama Study. Journal of the American 506 Heart Association. 2018 Jan 20;7(2). PubMed PMID: 29353232. Pubmed Central 507 PMCID: Pmc5850144. Epub 2018/01/22. eng. 508 36. Barzilay JI, Lovato JF, Murray AM, Williamson J, Ismail-Beigi F, Karl D, et al. 509 Albuminuria and cognitive decline in people with diabetes and normal renal function. 510 Clinical journal of the American Society of Nephrology : CJASN. 2013 511 Nov;8(11):1907-14. PubMed PMID: 23990163. Pubmed Central PMCID: Pmc3817915. 512 Epub 2013/08/31. eng. 513 Wei Y, Wei YK, Zhu J. Early markers of kidney dysfunction and cognitive 37. 514 impairment among older adults. Journal of the neurological sciences. 2017 Apr 515 15;375:209-14. PubMed PMID: 28320132. Epub 2017/03/23. eng. 516 38. Barzilay JI, Gao P, O'Donnell M, Mann JF, Anderson C, Fagard R, et al. 517 Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies.

medRxiv preprint doi: https://doi.org/10.1101/2023.09.24.23296045; this version posted September 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 518 Archives of internal medicine. 2011 Jan 24;171(2):142-50. PubMed PMID: 21263104. 519 Epub 2011/01/26. eng.
- 520 39. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, et al.

521 Current issues in measurement and reporting of urinary albumin excretion. Clinical

chemistry. 2009 Jan;55(1):24-38. PubMed PMID: 19028824. Epub 2008/11/26. eng. 522

523 Fried L. Albuminuria and cognitive impairment. Clinical journal of the 40. 524 American Society of Nephrology : CJASN. 2012 Mar;7(3):376-8. PubMed PMID:

525 22282483. Epub 2012/01/28. eng.

- 526 Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology, 41.
- mechanisms and management. Annals of translational medicine. 2014 Aug;2(8):80. 527
- 528 PubMed PMID: 25333055. Pubmed Central PMCID: Pmc4200648. Epub 2014/10/22. 529 eng.
- 530
- 531
- 532

|   | Estimated glo<br>Overall filtration(ml/mi |                | imated glomeru<br>ion(ml/min/1.7                 | ılar<br>3 m²)   | 5       | Urinary ACR (mg/g)                               |  |  |       |
|---|---|----------------|--|-----------------|---------|--|--|--|-------|
|   | o voiun                                   | ≥90            | 60-89  | <60             | -<br>P  | <30  | 30-300   | >300   | P     |
|   | n=608                                     | n=371          | n=207  | n=30            | value   | n=338  | n=240  | n=30   | value |
| Age, y                                      | $66.6 \pm 4.1$                            | $65.5\pm3.5$   | $68.0\pm4.5$                                     | $69.8\pm4.5$    | < 0.001 | $66.4\pm4.2$                                     | $66.8\pm4.1$                                     | $66.3 \pm 3.7$                                   | 0.45  |
| Male, n(%)                                  | 316 (52.0)                                | 192 (51.8)     | 105 (50.7)                                       | 19 (63.3)       | 0.43    | 186 (55.0)                                       | 115 (47.9)                                       | 15 (50.0)  | 0.235 |
| BMI, <sup>a</sup> kg/m <sup>2</sup>         | $25.0 \pm 3.6$                            | $24.8\pm3.4$   | $24.9\pm3.8$                                     | $26.6\pm4.0$    | 0.033   | $24.6 \pm 3.4$                                   | $25.3 \pm 3.7$                                   | $25.9 \pm 3.8$                                   | 0.019 |
| Education (> 6 years), n (%)                | 200 (32.9)                                | 130 (35.0)     | 58 (28.0)  | 12 (40.0)       | 0.158   | 113 (33.4)                                       | 77 (32.1)  | 10 (33.3)  | 0.943 |
| Systolic blood pressure on admission, mmHg  | $171.9 \pm 20.2$                          | $170.0\pm19.8$ | $\begin{array}{c} 174.2 \pm \\ 20.7 \end{array}$ | 178.9 ±<br>19.4 | 0.008   | $\begin{array}{c} 170.3 \pm \\ 18.4 \end{array}$ | $\begin{array}{c} 173.8 \pm \\ 22.1 \end{array}$ | $\begin{array}{r} 174.8 \pm \\ 23.3 \end{array}$ | 0.079 |
| Diastolic blood pressure on admission, mmHg | $92.9 \pm 12.2$                           | 92.1 ± 12.1    | $93.9 \pm 12.4$                                  | $96.5\pm12.7$   | 0.057   | 91.5 ±<br>11.7                                   | 94.6 ± 12.7                                      | 95.5 ± 12.8                                      | 0.006 |
| Smoking, n (%)                              |   |                |  |                 | 0.112   |  |  |  | 0.057 |
| Never                                       | 355 (58.5)                                | 229 (61.7)     | 114 (55.3)                                       | 12 (40.0)       |         | 182 (54.0)                                       | 153 (63.7)                                       | 20 (66.7)  |       |
| Former                                      | 64 (10.5)                                 | 33 (8.9)       | 26 (12.6)  | 5 (16.7)        |         | 34 (10.1)  | 26 (10.8)  | 4 (13.3)   |       |
| Current                                     | 188 (31.0)                                | 109 (29.4)     | 66 (32.0)  | 13 (43.3)       |         | 121 (35.9)                                       | 61 (25.4)  | 6 (20.0)   |       |
| Alcohol drinking, n (%)                     |   |                |  |                 | 0.474   |  |  |  | 0.18  |
| Never                                       | 389 (64.0)                                | 245 (66.0)     | 128 (61.8)                                       | 16 (53.3)       |         | 205 (60.7)                                       | 163 (67.9)                                       | 21 (70.0)  |       |
| Former                                      | 52 (8.6)                                  | 27 (7.3)       | 21 (10.1)  | 4 (13.3)        |         | 33 (9.8)   | 15 (6.2)   | 4 (13.3)   |       |
| Current                                     | 167 (27.5)                                | 99 (26.7)      | 58 (28.0)  | 10 (33.3)       |         | 100 (29.6)                                       | 62 (25.8)  | 5 (16.7)   |       |

Table 1 Demographic and clinical characteristics of patients stratified by eGFR and UACR

| Diabetes mellitus, <sup>b</sup> n (%)                          | 50 (8.2)       | 34 (9.2)         | 13 (6.3)       | 3 (10.0)        | 0.45    | 21 (6.2)   | 23 (9.6)        | 6 (20.0)       | 0.019   |
|--|----------------|------------------|----------------|-----------------|---------|--|-----------------|----------------|---------|
| Hypertension, n (%)  | 361 (59.4)     | 215 (58.0)       | 127 (61.4)     | 19 (63.3)       | 0.656   | 189 (55.9)                                       | 154 (64.2)      | 18 (60.0)      | 0.138   |
| Stroke subtypes  |                |                  |                |                 | 0.149   |  |                 |                | 0.911   |
| Large artery   | 281 (46.2)     | 183 (49.3)       | 80 (38.6)      | 18 (60.0)       |         | 156 (46.2)                                       | 110 (45.8)      | 15 (50.0)      |         |
| Small vessel occlusion   | 309 (50.8)     | 176 (47.4)       | 121 (58.5)     | 12 (40.0)       |         | 171 (50.6)                                       | 124 (51.7)      | 14 (46.7)      |         |
| Cardioembolism   | 13 (2.1)       | 9 (2.4)          | 4 (1.9)        | 0 (0.0)         |         | 8 (2.4)  | 4 (1.7)         | 1 (3.3)        |         |
| Other determined etiology                                      | 3 (0.5)        | 1 (0.3)          | 2 (1.0)        | 0 (0.0)         |         | 1 (0.3)  | 2 (0.8)         | 0 (0.0)        |         |
| Undetermined etiology  | 2 (0.3)        | 2 (0.5)          | 0 (0.0)        | 0 (0.0)         |         | 2 (0.6)  | 0 (0.0)         | 0 (0.0)        |         |
| Laboratory results   |                |                  |                |                 |         |  |                 |                |         |
| Total cholesterol, mmol/L                                      | 5.7 ± 1.2      | $5.6 \pm 1.1$    | $5.8 \pm 1.3$  | $5.8 \pm 1.3$   | 0.055   | $5.7 \pm 1.2$                                    | $5.7 \pm 1.2$   | $6.0 \pm 1.1$  | 0.423   |
| Triglyceride, mmol/L   | $1.6 \pm 0.9$  | $1.7 \pm 1.1$    | $1.5 \pm 0.7$  | $1.6 \pm 0.7$   | 0.036   | $1.5\pm0.8$                                      | $1.8 \pm 1.1$   | $1.6 \pm 0.5$  | 0.016   |
| Homocysteine, umol/L   | $16.1 \pm 9.4$ | $14.7\pm7.9$     | $17.0 \pm 8.6$ | $27.9 \pm 18.7$ | < 0.001 | $15.5 \pm 7.1$                                   | $17.0 \pm 11.7$ | 17.1 ± 10.2    | 0.124   |
| Uric Acid, mmol/L  | $298.6\pm75.4$ | $284.5 \pm 68.9$ | 312.3 ± 75.2   | 377.7 ±<br>89.6 | < 0.001 | $\begin{array}{c} 299.0 \pm \\ 71.8 \end{array}$ | 296.2 ± 79.5    | 313.0±<br>81.9 | 0.511   |
| Fasting glucose, mmol/L  | $6.1 \pm 1.8$  | $6.2 \pm 2.0$    | $6.1 \pm 1.6$  | $6.3 \pm 1.4$   | 0.698   | $6.0 \pm 1.7$                                    | $6.2\pm1.9$     | $6.7\pm2.5$    | 0.082   |
| Estimated glomerular filtration rate,mL/min/1.73m <sup>2</sup> | 88.4 ± 12.9    | 96.0 ± 5.3       | $79.8\pm8.5$   | $53.2\pm8.2$    | < 0.001 | 89.0 ±<br>11.9                                   | 88.3 ± 13.0     | 81.8 ±<br>19.8 | 0.013   |
| Log10 Urinary ACR  | $1.5 \pm 0.5$  | $1.5 \pm 0.5$    | $1.5 \pm 0.4$  | $1.7 \pm 0.7$   | 0.246   | $1.2 \pm 0.2$                                    | $1.8\pm0.3$     | $2.8\pm0.3$    | < 0.001 |
| Neural function assessment, mean (SD)                          |                |                  |                |                 |         |  |                 |                |         |
| MMSE score, mean $\pm$ SD (range 0–30)                         | $21.4 \pm 2.1$ | 22.0 ± 1.9       | 21.1 ± 1.6     | $17.5 \pm 2.8$  | < 0.001 | $21.5\pm2.0$                                     | $21.4 \pm 2.1$  | $20.8\pm2.9$   | 0.18    |

| MoCA score, mean $\pm$ SD (range 0–30)  | $17.9 \pm 2.3$ | $18.7 \pm 2.0$ | $17.2 \pm 1.9$ | $13.4 \pm 2.6$ | < 0.001 | $18.0 \pm 2.3$ | $17.9 \pm 2.3$ | $17.2 \pm 2.8$ | 0.18  |
|---|----------------|----------------|----------------|----------------|---------|----------------|----------------|----------------|-------|
| NIHSS score, mean $\pm$ SD (range 0–24) | $5.0 \pm 2.2$  | $5.1 \pm 2.3$  | $4.8 \pm 2.1$  | $5.6 \pm 1.8$  | 0.091   | 5.1 ± 2.2      | $4.8 \pm 2.1$  | $5.3 \pm 2.8$  | 0.302 |

Abbreviations: BMI, body mass index. UACR: urine albumin-creatinine ratio

Values are presented as mean ± SD for continuous variables and n (%) for categorical variables.

<sup>a</sup> BMI was calculated as weight in kilograms divided by height in meters squared.

<sup>b</sup>Diabetes mellitus was defined as self-reported physician diagnosed diabetes.

<sup>C</sup>Hypertension was defined as self-reported physician diagnosed hypertension.

|   |                       | MMSE              |         |                   |         | MoCA              |         |                   |         |  |  |
|---|-----------------------|-------------------|---------|-------------------|---------|-------------------|---------|-------------------|---------|--|--|
| Variables                                   | patients (%)          | Crude             |         | adjusted*         |         | Crude             |         | adjusted*         |         |  |  |
|   | •                     | β (95%CI)         | Р       |  |  |
| eGFR, (ml/min/<br>categories                | /1.73m <sup>2</sup> ) |                   |         |                   |         |                   |         |                   |         |  |  |
| ≥90   | 371(61)               | 0                 |         | 0                 |         | 0                 |         | 0                 |         |  |  |
| 60-90                                       | 207(34)               | -0.9 (-1.2, -0.6) | < 0.001 | -0.7 (-1.0, -0.3) | < 0.001 | -1.5 (-1.8, -1.2) | < 0.001 | -1.4 (-1.7, -1.0) | < 0.001 |  |  |
| <60   | 30(5)                 | -4.4 (-5.1, -3.8) | < 0.001 | -4.2 (-5.0, -3.4) | < 0.001 | -5.3 (-6.0, -4.5) | < 0.001 | -5.2 (-6.1, -4.4) | < 0.001 |  |  |
| eGFR per 5-<br>unit decline<br>UACR(mg/g) c | 608(100)<br>ategories | -0.4 (-0.5, -0.4) | < 0.001 | -0.4 (-0.5, -0.4) | < 0.001 | -0.5 (-0.6, -0.5) | < 0.001 | -0.6 (-0.7, -0.5) | < 0.001 |  |  |
| <30   | 338(56)               | 0                 |         | 0                 |         | 0                 |         | 0                 |         |  |  |
| 30-300                                      | 240(39)               | -0.1 (-0.4, 0.3)  | 0.716   | 0.0 (-0.3, 0.3)   | 0.971   | -0.0 (-0.4, 0.3)  | 0.858   | 0.0 (-0.3, 0.3)   | 0.826   |  |  |
| ≥300  | 30(5)                 | -0.7 (-1.5, 0.0)  | 0.064   | -0.3 (-1.0, 0.4)  | 0.387   | -0.8 (-1.7, 0.0)  | 0.065   | -0.2 (-0.9, 0.6)  | 0.68    |  |  |
| log-UACR                                    | 608(100)              | -0.2 (-0.6, 0.2)  | 0.262   | -0.0 (-0.4, 0.3)  | 0.784   | -0.3 (-0.6, 0.1)  | 0.214   | -0.0 (-0.4, 0.3)  | 0.834   |  |  |

Table 2 Linear regression analysis of the association between levels of eGFR and albuminuria measured by UACR and cognitive performance

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR: urine albumin-creatinine ratio

\*Adjusted for age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure and either baseline estimated glomerular filtration rate or UACR.

| Comparing UACR (30-300, >300 vs <30mg/g) |          |                        |                        | P for       | Com | P for                    |                           |             |
|--|----------|------------------------|------------------------|-------------|-----|--------------------------|---------------------------|-------------|
| Subgroups                                | <30      | 30-300                 | >300                   | interaction | ≥90 | 60-90                    | <60                       | interaction |
|  |          | ß(                     | 95%CI) P               |             |     | ß(                       | (95%CI) P                 |             |
| Gender                                   |          |                        |                        | 0.050       |     |                          |                           | 0.123       |
| Male                                     | 0        | 0.3 (-0.1, 0.7) 0.137  | -0.5 (-1.5, 0.4) 0.278 |             | 0   | -1.0 (-1.5, -0.5) <0.001 | -4.1 (-5.2, -3.1) < 0.001 |             |
| Female                                   | 0        | -0.4 (-0.8, 0.1) 0.104 | -0.2 (-1.2, 0.8) 0.703 |             | 0   | -0.5 (-1.0, -0.0) 0.050  | -4.4 (-5.7, -3.1) <0.001  |             |
| Age dichotom                             | ous      |                        |                        | 0.588       |     |                          |                           | 0.609       |
| Lower                                    | 0        | -0.0 (-0.5, 0.4) 0.842 | -0.7 (-1.7, 0.4) 0.215 |             | 0   | -0.8 (-1.3, -0.3) 0.002  | -5.8 (-7.4, -4.3) < 0.001 |             |
| Higher                                   | 0        | 0.1 (-0.4, 0.5) 0.717  | 0.3 (-0.7, 1.3) 0.503  |             | 0   | -0.8 (-1.2, -0.4) <0.001 | -3.9 (-4.6, -3.1) <0.001  |             |
| Systolic blood                           | pressure | e dichotomous          |                        | 0.657       |     |                          |                           | 0.149       |
| Lower                                    | 0        | -0.1 (-0.5, 0.4) 0.781 | -0.2 (-1.3, 0.9) 0.740 |             | 0   | -0.6 (-1.2, -0.1) 0.021  | -2.8 (-4.2, -1.4) < 0.001 |             |
| Higher                                   | 0        | 0.1 (-0.3, 0.5) 0.652  | -0.3 (-1.2, 0.7) 0.562 |             | 0   | -0.7 (-1.2, -0.2) 0.005  | -4.2 (-5.1, -3.3) <0.001  |             |
| NIHSS score d                            | lichotom | ious                   |                        | 0.375       |     |                          |                           | 0.953       |
| Lower                                    | 0        | -0.2 (-0.7, 0.3) 0.393 | -0.6 (-1.7, 0.5) 0.304 |             | 0   | -0.6 (-1.1, -0.0) 0.035  | -3.7 (-5.4, -2.0) < 0.001 |             |
| Higher                                   | 0        | 0.1 (-0.3, 0.5) 0.767  | -0.0 (-0.9, 0.9) 0.982 |             | 0   | -0.7 (-1.1, -0.2) 0.006  | -4.2 (-5.1, -3.3) <0.001  |             |
| Stroke<br>subtypes                       |          |                        |                        | 0.311       |     |                          |                           | 0.122       |
| Large artery                             | 0        | 0.1 (-0.4, 0.6) 0.661  | 0.3 (-0.7, 1.3) 0.531  |             | 0   | -0.8 (-1.4, -0.2) 0.006  | -4.3 (-5.3, -3.2) <0.001  |             |
| Small vessel occlusion                   | 0        | -0.2 (-0.6, 0.2) 0.330 | -0.4 (-1.4, 0.6) 0.441 |             | 0   | -0.5 (-1.0, -0.1) 0.026  | -4.0 (-5.3, -2.8) <0.001  |             |
| Blood glucose                            | dichotor | mous                   |                        | 0.849       |     |                          |                           | 0.372       |
| Lower                                    | 0        | -0.3 (-0.9, 0.2) 0.225 | -2.5 (-5.2, 0.1) 0.059 |             | 0   | -1.0 (-1.5, -0.5) <0.001 | -4.5 (-5.7, -3.4) <0.001  |             |

Table 3 Multivariable adjusted\* Linear regression of MMSE scores with UACR and eGFR within subgroups

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR: urine albumin-creatinine ratio

\*Adjusted, if not stratified, age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure and either estimated glomerular filtration rate or UACR.

|                        | Comparing UACR (30-300, >300 vs <30mg/g) |                        |                        | P for       | Com | P for                    |                           |             |
|------------------------|--|------------------------|------------------------|-------------|-----|--------------------------|---------------------------|-------------|
|                        | <30                                      | 30-300                 | >300                   | interaction | ≥90 | 60-90                    | <60                       | interaction |
| Subgroups              |  | ß                      | (95%CI) <i>P</i>       |             |     | ß                        | (95%CI) <i>P</i>          |             |
| Gender                 |  |                        |                        | 0.107       |     |                          |                           | 0.195       |
| Male                   | 0  | 0.3 (-0.1, 0.8) 0.149  | -0.1 (-1.1, 1.0) 0.910 |             | 0   | -1.7 (-2.2, -1.1) <0.001 | -5.4 (-6.5, -4.3) < 0.001 |             |
| Female                 | 0  | -0.3 (-0.8, 0.2) 0.197 | -0.2 (-1.3, 0.8) 0.673 |             | 0   | -1.1 (-1.7, -0.6) <0.001 | -4.8 (-6.2, -3.3) < 0.001 |             |
| Age dichotom           | ous                                      |                        |                        | 0.352       |     |                          |                           | 0.341       |
| Lower                  | 0  | 0.1 (-0.4, 0.6) 0.658  | -0.6 (-1.7, 0.6) 0.345 |             | 0   | -1.3 (-1.9, -0.7) <0.001 | -6.1 (-8.0, -4.3) < 0.001 |             |
| Higher                 | 0  | 0.1 (-0.4, 0.5) 0.819  | 0.4 (-0.6, 1.4) 0.411  |             | 0   | -1.4 (-1.9, -0.9) <0.001 | -5.1 (-6.1, -4.1) < 0.001 |             |
| Systolic blood         | pressu                                   | re dichotomous         |                        | 0.595       |     |                          |                           | 0.402       |
| Lower                  | 0  | 0.0 (-0.5, 0.5) 0.922  | 0.1 (-1.0, 1.3) 0.825  |             | 0   | -1.2 (-1.8, -0.7) <0.001 | -4.2 (-5.6, -2.7) <0.001  |             |
| Higher                 | 0  | 0.0 (-0.4, 0.4) 0.969  | -0.3 (-1.3, 0.7) 0.533 |             | 0   | -1.4 (-1.9, -0.9) <0.001 | -5.7 (-6.8, -4.6) < 0.001 |             |
| NIHSS score of         | dichotor                                 | nous                   |                        | 0.422       |     |                          |                           | 0.835       |
| Lower                  | 0  | -0.3 (-0.8, 0.3) 0.318 | -0.1 (-1.2, 1.1) 0.932 |             | 0   | -1.3 (-1.9, -0.7) <0.001 | -5.1 (-7.0, -3.3) <0.001  |             |
| Higher                 | 0  | -0.1 (-1.2, 1.1) 0.932 | -0.1 (-1.0, 0.9) 0.879 |             | 0   | -1.4 (-1.9, -0.9) <0.001 | -5.3 (-6.3, -4.4) < 0.001 |             |
| Stroke subtype         | es                                       |                        |                        | 0.391       |     |                          |                           | 0.576       |
| Large artery           | 0  | 0.3 (-0.2, 0.7) 0.277  | 0.2 (-0.8, 1.3) 0.653  |             | 0   | -1.4 (-2.0, -0.8) <0.001 | -4.9 (-6.0, -3.8) <0.001  |             |
| Small vessel occlusion | 0  | -0.2 (-0.7, 0.2) 0.310 | 0.1 (-1.0, 1.2) 0.825  |             | 0   | -1.3 (-1.8, -0.8) <0.001 | -5.7 (-7.1, -4.2) <0.001  |             |
| Blood glucose          | dichoto                                  | omous                  |                        | 0.409       |     |                          |                           | 0.585       |
| Lower                  | 0  | 0.0 (-0.4, 0.5) 0.960  | -0.5 (-1.5, 0.5) 0.303 |             | 0   | -1.7 (-2.3, -1.1) <0.001 | -5.3 (-6.6, -4.0) < 0.001 |             |
| Higher                 | 0  | -0.0 (-0.5, 0.4) 0.838 | -0.1 (-1.1, 1.0) 0.918 |             | 0   | -1.1 (-1.7, -0.6) <0.001 | -5.1 (-6.3, -3.9) <0.001  |             |

Table 4 Multivariable adjusted\* Linear regression of MoCA scores with UACR and eGFR within subgroups

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR: urine albumin-creatinine ratio

\*Adjusted, if not stratified, age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure and either estimated glomerular filtration rate or UACR.

|                                    |           | MN                | /ISE              | MoCA                  |                   |  |  |
|------------------------------------|-----------|-------------------|-------------------|-----------------------|-------------------|--|--|
| eGFR, (ml/min/1.73m <sup>2</sup> ) |           | UACR(mg/          | g) categories     | UACR(mg/g) categories |                   |  |  |
|                                    |           | <30               | ≥30               | <30                   | ≥30               |  |  |
| ≥90                                | Crude     | 0.00              | 0.0 (-0.4, 0.4)   | 0.00                  | 0.2 (-0.3, 0.6)   |  |  |
|                                    | Adjusted* | 0.00              | -0.0 (-0.4, 0.4)  | 0.00                  | 0.1 (-0.3, 0.6)   |  |  |
| <90                                | Crude     | -1.2 (-1.7, -0.8) | -1.5 (-2.0, -1.0) | -1.7 (-2.2, -1.3)     | -2.1 (-2.6, -1.6) |  |  |
|                                    | Adjusted* | -0.8 (-1.3, -0.4) | -1.0 (-1.5, -0.5) | -1.4 (-1.9, -0.9)     | -1.7 (-2.3, -1.2) |  |  |

#### Table 5 Association of joint UACR and eGFR stratum with cognitive performance (β 95% CI)

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR, urine albumin-creatinine ratio.

\* adjusted for age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure.